SGLT2 inhibitors: β blockers for the kidney?

Lancet Diabetes Endocrinol. 2016 Oct;4(10):814. doi: 10.1016/S2213-8587(16)30237-6.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Adrenergic beta-Antagonists
  • Diabetes Mellitus, Type 2
  • Humans
  • Hypoglycemic Agents
  • Kidney*
  • Sodium-Glucose Transporter 2*

Substances

  • Adrenergic beta-Antagonists
  • Hypoglycemic Agents
  • Sodium-Glucose Transporter 2